Low-Dose Cytosine Arabinoside Therapy for Neonates with Down Syndrome (DS) and Transient Leukemia (TL).
Hideki Muramatsu(Nagoya University), Akira Kikuchi(The University of Osaka), Takashi Taga(Erasmus MC), Aiko Sumie, Atsushi Manabe(St. Luke's International Hospital), Miharu Yabe(Tokai University), Masahiro Tsuchida, Seiji Kojima(Saitama Children's Medical Center), Keiichi Isoyama(Showa University Fujigaoka Hospital), Hiromi Kato, Daisuke Hasegawa(Icahn School of Medicine at Mount Sinai), Etsuro Ito(Okayama University), Tomohiko Taki(Kyorin University), Yasuhide Hayashi(Gunma Children's Medical Center), Keiko Nomura(Osaka Gakuin University), Kohichiro Tsuji(Tokyo Medical University), Shotaro Iwamoto(St. Jude Children's Research Hospital), Kenichiro Watanabe(University Hospital of Geneva)
Cited by 0
Related Papers
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
|Nature Genetics|2016|473
Unification of Hematopoietic Stem Cell Transplantation Registries in Japan and Establishment of the TRUMP System
|International Journal of Hematology|2007|345
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase
|Journal of Clinical Investigation|2007|335
Wnt5a regulates distinct signalling pathways by binding to Frizzled2
|The EMBO Journal|2009|319